BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Label on Genentech (RHHBY)'s Avastin Warns of Infertility


10/5/2011 7:54:00 AM

By Ron Leuty, Reporter - San Francisco Business Times

The world’s best-selling cancer drug, Genentech Inc.’s Avastin, now carries a warning about increased risk of infertility in premenopausal women.

The Food and Drug Administration said Avastin’s label as of Sept. 30 includes the new warning regarding “ovarian failure.” Data suggest that some women with the potential of bearing children may become infertile as a result of Avastin and should talk to their doctor before starting treatment, the FDA said.

The new label also lists a degenerative jawbone condition as an adverse reaction, along with the risk of blood clots in the veins and the risk of bleeding in metastatic colorectal cancer patients receiving anti-clotting therapy after an initial blood clot while receiving Avastin.

Both South San Francisco-based Genentech and the FDA said the new information is part of a routine label update.

Avastin has been at the center of a national debate about its conditional approval for women with metastatic breast cancer. FDA Commissioner Margaret Hamburg is weighing an advisory committee's recommendation this summer to revoke that approval because, they said, the risks of the $80,000-a-year drug outweigh the benefits those women live longer without the disease progressing.

The label change is for all cancer types for which Avastin is approved — metastatic breast cancer, and types of non-small cell lung cancer, brain cancer, metastatic colorectal cancer and metastatic renal cell carcinoma — Genentech spokeswoman Charlotte Arnold said.

While Avastin was in preclinical studies — years before it was first approved as a first-line treatment for metastatic colorectal cancer in 2004 — Genentech researchers identified ovarian failure as a possible side effect, Arnold said. Genentech, now a unit of Swiss drug maker Roche, agreed at the time Avastin was initially approved to study the infertility issue further as part of another Phase III study, data from which was used to make this labeling change.

Genentech said it also will issue a letter to health-care professionals about the risk of ovarian failure that is based on that failed study in early-stage colon cancer.



Read at San Francisco Business Times
Read at Fox News
Read at FDA

Genentech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES